Last reviewed 2026-05-29 · How we verify

NADOXOLOL

Phase 2 active Small molecule ✓ Verified May 2026

NADOXOLOL is a nadoxolol drug. It is currently in Phase 2 development.

Nadoxolol is a beta-adrenergic receptor blocker that works by blocking the effects of the hormone epinephrine, also known as adrenaline.

Nadoxolol is a small molecule. It is also known by the synonyms LL 1530 and Nadoxolol.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	NADOXOLOL
Drug class	nadoxolol
Modality	Small molecule
Therapeutic area	Nephrology
Phase	Phase 2

Mechanism of action

Think of it like a volume control for your heart. When you're stressed or excited, your body releases epinephrine, which makes your heart beat faster. Nadoxolol helps slow down your heart rate by blocking the effects of epinephrine, making it easier to manage conditions like high blood pressure or heart disease.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NADOXOLOL CI brief — competitive landscape report
NADOXOLOL updates RSS · CI watch RSS

Frequently asked questions about NADOXOLOL

What is NADOXOLOL?

NADOXOLOL is a nadoxolol drug.

How does NADOXOLOL work?

Nadoxolol is a beta-adrenergic receptor blocker that works by blocking the effects of the hormone epinephrine, also known as adrenaline.

What drug class is NADOXOLOL in?

NADOXOLOL belongs to the nadoxolol class. See all nadoxolol drugs at /class/nadoxolol.

What development phase is NADOXOLOL in?

NADOXOLOL is in Phase 2.

Drug class: All nadoxolol drugs
Therapeutic area: All drugs in Nephrology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing